Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice

Cancer Letters

Volumn 339, Issue 1, 2013, Pages 144-151

  Starenki, Dmytro ^a   Singh, Nishant K ^a   Jensen, Davin R ^a   Peterson, Francis C ^a   Park, Jong In ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Leukemia inhibitory factor; Medullary thyroid carcinoma; RET; STAT3

Indexed keywords

EMFILERMIN; JANUS KINASE; PROTEIN RET; STAT PROTEIN; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; CYTOSTASIS; DOWN REGULATION; DRUG ACTIVATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

LEUKEMIA INHIBITORY FACTOR; LIF; MALDI-TOF; MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME-OF-FLIGHT; MEDULLARY THYROID CARCINOMA; MEN; MTC; MULTIPLE ENDOCRINE NEOPLASIA; PBS; PHOSPHATE-BUFFERED SALINE; REARRANGED DURING TRANSFECTION; RET; STAT3;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; JANUS KINASES; LEUKEMIA INHIBITORY FACTOR; MICE; PROTO-ONCOGENE PROTEINS C-RET; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; THYROID NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84883464713     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.006     Document Type: Article

References (42)

1. Tuttle R.M., Ball D.W., Byrd D., Daniels G.H., Dilawari R.A., Doherty G.M., et al. Medullary carcinoma. J. Natl. Compr. Canc. Netw. 2010, 8:512-530.
2. Agrawal N., Jiao Y., Sausen M., Leary R., Bettegowda C., Roberts N.J., et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J. Clin. Endocrinol. Metab. 2013, 98:E364-E369.
3. Boichard A., Croux L., Al Ghuzlan A., Broutin S., Dupuy C., Leboulleux S., et al. J. Clin. Endocrinol. Metab. 2012, 97:E2031-E2035.
4. Ciampi R., Mian C., Fugazzola L., Cosci B., Romei C., Barollo S., et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013, 23:50-57.
5. Ichihara M., Murakumo Y., Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 2004, 204:197-211.
6. Degrauwe N., Sosa J.A., Roman S., Deshpande H.A. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin. Med. Insights Oncol. 2012, 6:243-252.
7. Nagilla M., Brown R.L., Cohen E.E. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv. Ther. 2012, 29:925-934.
8. Wells S.A., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 2012, 30:134-141.
9. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
10. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998, 12:2997-3007.
11. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998, 12:3008-3019.
12. Park J.I., Strock C.J., Ball D.W., Nelkin B.D. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol. Cell Biol. 2003, 23:543-554.
13. Arthan D., Hong S.K., Park J.I. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett. 2010, 297:31-41.
14. Auernhammer C.J., Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Rev. 2000, 21:313-345.
15. Kim E.J., Park J.I., Nelkin B.D. IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J. Biol. Chem. 2005, 280:4913-4920.
16. La Thangue N.B. The yin and yang of E2F-1: balancing life and death. Nat. Cell Biol. 2003, 5:587-589.
17. Choubey D., Deka R., Ho S.M. Interferon-inducible IFI16 protein in human cancers and autoimmune diseases. Front. Biosci. 2008, 13:598-608.
18. Park J.I., Strock C.J., Ball D.W., Nelkin B.D. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 2005, 29:125-134.
19. Starenki D., Park J.I. Mitochondria-targeted nitroxide, mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. J. Clin. Endocrinol. Metab. 2013, 98:1529-1540.
20. Love M., Sandberg J.L., Ziarek J.J., Gerarden K.P., Rode R.R., Jensen D.R., et al. Solution structure of CCL21 and identification of a putative CCR7 binding site. Biochemistry 2012, 51:733-735.
21. de Groot J.W., Plaza Menacho I., Schepers H., Drenth-Diephuis L.J., Osinga J., Plukker J.T., et al. Surgery 2006, 139:806-814.
22. Morisi R., Celano M., Tosi E., Schenone S., Navarra M., Ferretti E., et al. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J. Endocrinol. Invest. 2007, 30:RC31-4.
23. Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., Links T.P., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem. 2007, 282:29230-29240.
24. Jansson J.O., Moverare-Skrtic S., Berndtsson A., Wernstedt I., Carlsten H., Ohlsson C. Leukemia inhibitory factor reduces body fat mass in ovariectomized mice. Eur. J. Endocrinol. 2006, 154:349-354.
25. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
26. Wells S.A., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol.: Official Journal of the Am. Soc. Clin. Oncol. 2012, 30:134-141.
27. Schoffski P., Elisei R., Müller S., Brose M.S., Shah M.H., Licitra L.F., Jarzab B., Medvedev V., Kreissl M., Niederle B., Cohen E.E.W., Wirth L.J., Ali H.Y., Hessel C., Yaron Y., Ball D.W., Nelkin B., Sherman S.I., Schlumberger M. EXAM study group. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J. Clin. Oncol. 2012, 30. Abstract 5508.
28. Park J.I., Powers J.F., Tischler A.S., Strock C.J., Ball D.W., Nelkin B.D. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Exp. Cell Res. 2005, 303:79-88.
29. Schuringa J.J., Wojtachnio K., Hagens W., Vellenga E., Buys C.H., Hofstra R., et al. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 2001, 20:5350-5358.
30. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
31. Song J.I., Grandis J.R. STAT signaling in head and neck cancer. Oncogene 2000, 19:2489-2495.
32. Subramaniam A., Shanmugam M.K., Perumal E., Li F., Nachiyappan A., Dai X., et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim. Biophys. Acta 2013, 1835:46-60.
33. Couto J.P., Daly L., Almeida A., Knauf J.A., Fagin J.A., Sobrinho-Simoes M., et al. STAT3 negatively regulates thyroid tumorigenesis. Proc. Natl. Acad. Sci. USA 2012, 109:E2361-E2370.
34. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
35. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
36. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
37. Lee N.C., Norton J.A. Multiple endocrine neoplasia type 2B-genetic basis and clinical expression. Surg. Oncol. 2000, 9:111-118.
38. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4:11-22.
39. Farese A.M., Myers L.A., MacVittie T.J. Therapeutic efficacy of recombinant human leukemia inhibitory factor in a primate model of radiation-induced marrow aplasia. Blood 1994, 84:3675-3678.
40. Kurek J.B., Radford A.J., Crump D.E., Bower J.J., Feeney S.J., Austin L., et al. LIF (AM424), a promising growth factor for the treatment of ALS. J. Neurol. Sci. 1998, 160(Suppl. 1):S106-S113.
41. Davis I.D., Kiers L., MacGregor L., Quinn M., Arezzo J., Green M., et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin. Cancer Res. 2005, 11:1890-1898.
42. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 2003, 21:5-14.